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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
This review aims to look at the benefits and harms of using eHealth interventions in the CKD population.
B A C K G R O U N D
Description of the condition
Chronic kidney disease (CKD) is increasingly being recognised
as a global public health problem with increasing incidence and
prevalence, high costs and poor outcomes (Couser 2011; Levey
2005; Levey 2007). CKD is defined as kidney damage or a mea-
sured glomerular filtration rate (GFR) of less than 60 mL/min/
1.73 m2 for more than three months or by the presence of albu-
minuria in two to three spot urine tests (Levey 2005). Poorer pa-
tient outcomes and increasing costs are associated with worsening
kidney function (Levey 2005).
As CKD progresses it is associated with substantially increased
morbidity and mortality. Mortality associated with end-stage kid-
ney disease (ESKD) is 10 to 100 times greater than for age-matched
controls with normal kidney function (Couser 2011). Increasing
severity of CKD is associated with increased all-cause mortality
and cardiovascular disease (CVD) mortality, kidney disease pro-
gression requiring life-saving dialysis treatment, acute kidney in-
jury, cognitive decline, anaemia, bone and mineral disorders and
bone fractures, and increased hospitalisation and health care usage
(Jha 2013; Stevens 2013).
The burden of CKD is rising, as shown by an increase in at-
tributable deaths and the increased incidence and prevalence of
ESKD. CKD is especially common in people with other chronic
diseases, notably diabetes, hypertension and cardiovascular dis-
ease, and multiplies the risk for adverse outcomes and increases
costs (Couser 2011; Levey 2007). The prevalence of CKD is esti-
mated to affect 8% to 16% of people worldwide (Jha 2013), with
the annual growth of ESKD treatments ranging from 6% to 12%
over the past two decades (Couser 2011).
It has been estimated that developed countries spend approxi-
mately 2% to 3% of their annual health care budget on ESKD,
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with earlier stages of CKD costing approximately double this
(Couser 2011; Jha 2013). The economic burden of CKD has not
been well evaluated in developing countries but it is expected to
be higher than in developed countries (Jha 2012).
Description of the intervention
Patient engagement and self-management are the cornerstones of
optimal chronic disease management. Current literature regarding
patient self-management, education and engagement in the CKD
population is lacking. Literature indicates an improvement in pa-
tient knowledge, improvement in health-related quality of life, de-
layed need for dialysis, improved clinical outcomes, improved ad-
herence to therapeutic treatments and medications and increased
survival when utilising self-management programs (Bonner 2014;
Chen 2011; Devins 2005). It has also been noted that interven-
tions incorporating cognitive or behavioural components regard-
ing adherence to diet, fluid, medication and dialysis treatment are
more effective in the haemodialysis population (Matteson 2010).
However, there are few randomised controlled trials (RCT) and
within these there are significant variations in length of interven-
tions, study designs, outcomes assessed and measurement of out-
comes (Bonner 2014; Matteson 2010).
With CKD and renal replacement therapy rising, it is essential to
find innovative and efficient ways to engage with this patient pop-
ulation and improve health behaviours and outcomes. Delivering
patient-centred care and optimising self-management is a priority,
to control risk factors and improving disease management (Tong
2007). Modifiable CKD risk factors such as weight, blood glu-
cose control, blood pressure (BP) control and poor dietary intake
are associated with increasing morbidity and mortality (Couser
2011). The World Health Organization has recommended that
interventions focus on effective methods, including cost effective
methods, to control modifiable risk factors such as lifestyle in-
terventions, reducing hypertension, improving glycaemic control
and cardiovascular risk factors (e.g. dyslipidaemia) (Couser 2011).
Electronic health (eHealth) has been defined as an“emerging field
in the intersection of medical informatics, public health and busi-
ness, referring to health services and information delivered or en-
hanced through the Internet and related technologies…the term
characterizes not only a technical development, but also a state-
of-mind, a way of thinking, an attitude, and a commitment for
networked, global thinking, to improve health care locally, region-
ally, and worldwide by using information and communication
technology” (Eysenbach 2001). eHealth interventions encompass
internet-based systems, telemedicine, mobile phone technologies
(e.g. text messaging, mobile phone applications), consumer health
informatics, and healthcare information systems using computer-
based technologies.
Worldwide there has been a tremendous increase in the use of
technologies. The use of the Internet inAmerica has increased from
52% in 2000 to 84% in 2015, and currently it is estimated that
89% of Americans own amobile phone, with 64% owning a smart
phone (Perrin 2015; Smith 2015). Whilst rates of Internet and
phone use are lower in developing countries there is a similar trend.
It is currently estimated that 86% of people own a mobile phone,
66% use the Internet, and 38% own a computer (Pew Research
Center 2015). Use of technology is associated with younger age,
higher education attainment and higher socio-economic groups
(Perrin 2015; Smith 2015). In the chronic disease population it
has been estimated that 62% use the Internet and 51% use the
Internet to look for medical information (Fox 2010). There is
currently no published data regarding the use of technology in the
CKD population.
There is a variety of different eHealth modalities reported in the
literature, including:
• Telehealth technologies
• Mobile phone based (including text messaging and the use
of applications on mobile phones)
• Internet and computer based
• Mixed methods (incorporating telehealth, Internet and
mobile phone technologies)
Within these eHealth interventions there is wide use of these tools,
which can be categorised in two ways:
• Patient self-management interventions
• Clinician decision support tools
These varying eHealth interventions are also employed in various
ways:
• eHealth in addition to usual care
• eHealth as a stand-alone intervention
Recently there has been an increase in availability of eHealth in-
terventions aiming to improve chronic disease management and
patient outcomes. With the bourgeoning use of technologies in all
facets of people’s lives, technology provides a new opportunity to
engage with people to improve health behaviours. eHealth offers
the opportunity to reach those populations who are most at risk
of reduced access to healthcare and worse health outcomes (e.g.
remote communities, lower socio-economic groups, developing
countries) with high uptake of technology in these populations.
With more people using technology, the development, adoption
and implementation of eHealth holds tremendous promise to im-
prove consumer access to relevant health information, enhance the
quality of care and encourage the adoption of healthy behaviours.
How the intervention might work
In the CKD population, achieving some understanding of the
disease condition is an important component of promoting self-
management and shared decision making that can contribute to
improvedmedication compliance (e.g. medications relating to BP,
renal bone disease and proteinuria), avoiding potentially nephro-
toxic substances (e.g. non-steroidal anti-inflammatory medica-
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tions), attending appointments and improving health-related be-
haviours (e.g. diet, exercise and smoking cessation) (Fraser 2013).
The prevention of CKD, and delaying its progression to ESKD,
requires complex care because it involves both specific CKDman-
agement, as well as management of other prevalent co-morbidi-
ties (Lopez-Vargas 2014). Therefore, employing novel strategies
to improve the current management of this disease is vital.
Currently, there is limited literature regarding the use of eHealth
technologies in theCKDpopulation. A review exploring the effec-
tiveness of telehealth in kidney care (studies included pre-dialysis,
dialysis-dependent and post kidney transplant patients) found that
this was a variable alternative to face-to-face care in terms of clini-
cal outcomes and patient satisfaction (Blinkhorn 2012).However,
there was only a small number of studies, only one of which was a
RCT. The author highlighted the lack of available literature in the
CKD population compared to other chronic disease conditions.
However, as review did not include studies involving other tech-
nological interventions such as computer or mobile phone tech-
nologies, further review of the literature in CKD is warranted.
Clinical outcomes
eHealth interventions have shown mixed results in a range of clin-
ical outcomes when compared to usual care or non eHealth inter-
ventions.
Cardiovascular disease
A review by Widmer 2015 reported significant improvements in
a number of CVD clinical outcomes with the use of digital health
interventions over a six to 12 month period in a mixed CVD pop-
ulation (primary care, secondary care and heart failure). In those
studies which contained analysable CVD outcome data, a signifi-
cant 40% relative risk reduction in CVD outcomes (e.g. myocar-
dial infarction, stroke, revascularisation, hospitalisation) and all-
cause mortality and a significant 1.25% reduction in the Fram-
ingham 10 year risk percentages was reported. However, as only
a small subset of studies contained analysable data and as such
this effect size should be interpreted with caution. It was reported
that there was also a significant reduction in CVD risk factors,
weight, body mass index, cholesterol levels and BP, in secondary
and heart failure populations. The most efficacious interventions
were web, text messaging or telemedicine, with no effect reported
with email-based interventions.
Diabetes
In a review by Zhai 2014 a significant improvement in glycaemic
control, measured using HbA1c, when analysing all telemedicine
modalities. Pooled analyses showed significant improvement in
glycaemic control with both internet-based and phone-based in-
terventions (in addition to usual care). However, there was no
change in glycaemic control when analysing interventions using
internet transmission (e.g. patients uploading blood results using
the Internet, telephone or Bluetooth).
A meta-analysis conducted by Pal 2013 showed a small but signifi-
cant improvement in HbA1c of 0.2% of all eHealth interventions
compared to control; this improvement was more pronounced
in mobile phone based interventions with a 0.5% reduction in
HbA1c. It was noted that in interventions measuring outcomes
greater than sixmonths there were no statistical significant changes
in glycaemic control, suggesting that the effects of these interven-
tions may wear off (Pal 2013).
Cotter 2014 reported no significant change when using various
eHealth interventions in HbA1c levels in a type 2 diabetic popu-
lation. Those studies that did show improvements included inter-
active components with tracking and personalized feedback, and
provided opportunities for peer support.
Smoking cessation
A number of eHealth technologies, particularly mobile phone in-
terventions have shown promising results. It has been reported
that the use of intensive, personalised mobile phone interven-
tions, in the form of text messages, (Free 2011; Rogers 2005;
Whitaker 2016) have greater impact in smoking cessation for six
weeks or longer, when compared to usual care or passive interven-
tions. Intensive, personalised text messaging interventions have
been shown to double quit rates at six weeks (Rogers 2005) and
six months (Free 2011) when compared to usual care. These pos-
itive results were also reflected in a meta-analysis conducted by
Whitaker 2016 which showed a significant 71% increase in long-
term quit rates when comparing personalised, intensive text mes-
sage interventions when compared to usual care. However a sys-
tematic review conducted by Civljak 2013 failed to show any sig-
nificant improvements in smoking cessation with the use of in-
teractive, tailored internet-based interventions. There was some
evidence that interactive Internet-based interventions were more
effective at improving long-term quit rates than usual care (e.g.
printed self-help books), however this was not significant. There
was no difference found between interactive, tailored internet-
based interventions versus interactive non-internet-based inter-
ventions (e.g. phone and face-to-face counselling) and passive in-
ternet-based interventions.
Weight loss
Approximately 50% of technology-based weight loss studies re-
ported a significant reduction in weight compared to controls in a
systematic review conducted by Raajimakers 2015. Five key com-
ponents that enhanced technology-based interventions included:
self-monitoring, counsellor feedback and communication, group
support, the use of a structured program and the use of individ-
ually tailored programs. It was reported that interventions incor-
porating four to five of these components showed significantly
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greater weight loss when compared to usual care, while those stud-
ies incorporating only one to three of these strategies had mixed
results (Raajimakers 2015).
Mixed outcome measures
Murray 2005 and Hamine 2015 conducted systematic reviews in
mixed chronic disease populations using internet-based and mo-
bile phone based interventions (known as mHealth), respectively.
Murray 2005 reported no change in a range of clinical outcomes,
including urinary incontinence, weight and HbA1c with the use
of internet-based interventions that incorporated at least one com-
ponent of social support, decision support, or behaviour change
support. Less than half (39%) of studies reported significant im-
provements in clinical outcomes with the use of mHealth inter-
ventions. Clinical outcome measures were reported in diabetes
(HbA1c, frequency of hypoglycaemic events, and changes in in-
sulin dosage), CVD (changes in BP, lipid profile and CVD risk
profile) and chronic lung disease (indicators of lung function, use
of nebulizers, and exercise tests) (Hamine 2015).
A systematic review conducted by Beratarrechea 2014 investigated
the use of mobile phone interventions used in chronic disease
in developing countries reported positive results. Significant im-
provements in pulmonary function were reported in Taiwan and
Croatia with the use of a text message intervention. Similarly, text
message interventions in Poland and India showed significant im-
provements in glycaemic control, measured usingHbA1c.While a
study conducted in Uruguay showed no significant improvement
in HbA1c when utilising an internet-based plus text message in-
tervention, it was noted that uptake of this intervention was very
poor, particularly with respect to the internet-based component.
This review indicates that mobile health interventions are emerg-
ing as a useful to improve clinical endpoints in developing coun-
tries, however there are limited studies and the authors recom-
mend future research is needed.
Patient-centred outcomes
Patient-centred outcomes are related to “survival, function, symp-
toms, and health-related quality of life”. It “incorporates a wide
variety of settings and diversity of participants to address individ-
ual differences and barriers to implementation and dissemination
and investigates optimizing outcomes while addressing burden to
individuals, resource availability, and other stakeholder perspec-
tives” (Patient Centred Outcomes Research 2013).
Patient engagement
eHealth interventions have shown promise in improving patient
engagement. In a systematic review exploring various eHealth
interventions including, Internet, mobile phone, telehealth and
health information management tools, showed an improvement
in patient engagement and improvement in clinical outcomes
(Barello 2015). However, similarly to face-to-face interventions,
quality of the patients’ experience should be paramount when de-
signing these interventions, with the need to undertake a holistic
viewof the patient and tobe able to directly engagewith the patient
about their healthcare (Barello 2015). This was also highlighted
in a review of the efficacy of online patient portals which found
that early patient engagement in the development of these pro-
grams regarding health literacy and usability led to better uptake
and engagement of the intervention (Irizarry 2015). Additionally,
providing personalised, tailored information was more effective
(Irizarry 2015). There is a paucity of available research and signif-
icant heterogeneity in the eHealth landscape and this hinders any
assertion regarding the most efficacious interventions to enhance
patients’ self-management. Barriers to eHealth include access to
technology, technology literacy and technical issues (Barello 2015;
Irizarry 2015).
Adherence
Improvement in adherence and attendance rates was mixed
(Beratarrechea 2014;Hamine 2015). Beratarrechea 2014 reported
improved clinic attendance in the majority of studies which used
text message reminders. Tailored text message interventions were
found to significantly improve medication adherence in diabetic,
CVD and chronic lung disease populations, however increased ad-
herence was reported in only 56% of mobile phone-based studies
(Hamine 2015).
Health-related quality of life and social support
Two reviews reported on social support and health related quality
of life (Murray 2005; Pal 2013). In Pal 2013 the use of interactive
computer based interventions in a diabetic population showed ei-
ther small improvements or no change in mood, health related
quality of life or physical activity. In a mixed chronic disease popu-
lation, including both adults and children, computer and internet-
based interventions had a significantly positive effect on social sup-
port and a likely positive impact on self-efficacy (Murray 2005).
Murray 2005 also reported non-significant positive impacts on
behavioural outcomes such as physical activity, dietary intake and
attendance.
Diet and physical activity
A systematic review by Cotter 2014 investigating the effective-
ness of internet-based interventions in type 2 diabetes showed no
significant changes in dietary behaviours or physical activity lev-
els. These internet-based applications provided a variety of mech-
anisms to promote behaviour modification, ranging from static
education, to structural goal setting and progress tracking tools to
platforms for social support. The authors noted that similarly to
non-internet-based interventions, achieving adherence to healthy
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behaviours over time is one of the biggest challenges for any inter-
net-based behavioural intervention. They also noted that Internet
utilisation reduces over time; however there is not enough evi-
dence to suggest optimal patterns or length of use with the current
research.
Usability and acceptability
There is limited reported data regarding usability, feasibility and
acceptability. In a review by Hamine 2015 it was reported that
overall usability, feasibility and acceptability were high among end-
users and that these interventions contributed to increased self-
management awareness and knowledge about the chronic disease.
It was also highlighted that there was good comprehension and
satisfaction across diverse populations (low income, bilingual pop-
ulations and difficult to reach populations) and features such as
automated reminders, text messages with education and motiva-
tional content, healthy living challenges and wireless transmission
of data contributed to increased reported self-management aware-
ness and knowledge about disease management (Hamine 2015).
Cost effectiveness
Data regarding the cost-effectiveness of eHealth interventions was
limited. Beratarrechea 2014 reported reduced costs associatedwith
employing a text message appointment reminder system and it was
estimated that text message interventions cost 35% to 45% less
than telephone-based reminder systems. Zhai 2014 and Murray
2005 reported it was not possible to draw conclusions regarding
the cost effectiveness of the eHealth interventions due to limited
data.
eHealth interventions are becoming seen as a viable option to pro-
mote behaviour change, disease management and improve clin-
ical outcomes in many different for chronic disease conditions.
There are promising outcomes of using eHealth interventions,
when used in additional to traditional counselling techniques, for
improving disease management in chronic disease populations.
However there is a paucity of well-designed studies and further re-
search is needed to ascertain the optimal type, intensity and dura-
tion of eHealth strategies to most effectively elicit knowledge and
behaviour change. However, given the current literature showing
positive trends for the use of eHealth in chronic disease manage-
ment and health behaviour change, it is foreseeable that the CKD
population could also benefit from the use of eHealth interven-
tions.
Why it is important to do this review
This review is important for a number of reasons:
1. With CKD rising, effective strategies for improving patient
outcomes, improving the effectiveness of our interventions and
reducing costs is vital to reduce morbidity and mortality
associated with all stages of CKD worldwide.
2. eHealth interventions are becoming more common and
people are becoming more reliant on technology across all age
groups. There is a revolution in the modern health care system
powered by the growth of different health information
technologies that hold tremendous promise for enhancing the
delivery of health care (Kreps 2010). Whilst there has been a
large increase in the number studies investigating eHealth
interventions due to significant heterogeneity, with respect to
methods and chronic disease groups, it is unclear what the most
efficacious interventions are. It is vital to determine which
eHealth strategies are effective in improving CKD management
and patient outcomes.
O B J E C T I V E S
This review aims to look at the benefits and harms of using eHealth
interventions in the CKD population.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alteration, use of alternate medical records, date
of birth or other predictable methods) will be included.
Types of participants
Adults and children who have been diagnosed with CKD will be
included in this study.
Diagnosis of CKD is defined by estimated GFR (eGFR) less than
60mL/min or, eGFR less than 90 mL/min with albuminuria or
haematuria, for at least 3months or as definedusing other clinically
indicated criteria.
Types of interventions
Any interventions that the authors report to be using eHealth
technologies to promote behaviour change in CKD. eHealth tech-
nologies include:
• Telephone and Telehealth
• Mobile phone (including applications available on these
devices)
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• Computers and tablets (including applications available on
these devices)
• Personal Digital Assistants
• Internet (including e-mail)
• Electronic transmission (e.g. using technologies such as
Bluetooth)
• Social Media
• Electronic decision support tools
The comparisons will be as follows.
1. eHealth intervention versus non-eHealth intervention
2. eHealth intervention versus alternate eHealth intervention
3. eHealth intervention versus no intervention or usual care
If meta-analysis are possible, technologies of the same classifica-
tions (e.g. online or web) will be grouped together for analysis. If
possible, meta-regression analysis will be used to determine what
elements of the eHealth interventions were most effective.
Types of outcome measures
Time intervals at which outcome assessment takes place may affect
the effect of the intervention programs. We will consider all time
frames used by authors.
1. Changes in clinical parameters
◦ Change electrolyte management (measured using
biochemical measurements)
◦ Change in kidney function (measured using eGFR
and/or serum creatinine)
◦ Change in fluid management (measured using inter-
dialytic weight gains)
◦ Change in co-morbidities (measured using BP control,
dyslipidaemia, HbA1c, fasting and random blood glucose
readings, anthropometry)
◦ Hospitalisation rates
◦ Mortality
2. Changes in patient parameters
◦ Dietary intake and behaviours (measured using self-
reported data and qualitative and quantitative surveys)
◦ Physical activity behaviours (using validated tools,
quantitative and qualitative surveys, self-reported data)
◦ Adherence to treatment, including appointments
(using validated or self-reported data)
1. ◦ Quality of life (measured using validated tools such as
the SF-36 which exploring vitality, physical functioning, pain,
health perception, mental health and social, physical and
emotion role function)
◦ Nutritional status (measured using validated tools)
◦ Changes in self-management and self-efficacy
◦ satisfaction with interventions
2. Cost effectiveness
◦ Incremental cost-effectiveness ratios (defined as the
cost per quality-adjusted life year gained)
◦ Cost per Disability Adjusted Life Years (DALY)
◦ Costs associated with eHealth intervention
4. Potential harms
◦ Additional patient or health professional time
associated with the use of eHealth intervention
◦ Accidents or accidental deaths associated with using
the eHealth intervention (e.g. reading text message while driving)
Search methods for identification of studies
Electronic searches
We will search the Cochrane Kidney and Transplant Specialised
Register through contact with the Information Specialist using
search terms relevant to this review. The Specialised Register con-
tains studies identified from several sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of clinical practice guidelines, review articles
and relevant studies
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
3. Published governmental reports and white papers
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts will be screened independently by two authors who
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will discard studies that are not applicable. However, studies and
reviews that might include relevant data or information on studies
will be retained initially. Two authors will independently assess
retrieved abstracts, and if necessary the full text, of these studies
to determine which studies satisfy the inclusion criteria.
Data extraction and management
Data extraction will be carried out independently by the same
authors using standard data extraction forms. Studies reported in
non-English language will be translated before assessment. Where
more than one publication of a study exists, only the publication
with themost complete data will be included. Where relevant out-
comes are only published in earlier versions these data will be used.
Any discrepancy between published versions will be highlighted.
Any further information required from the original author will
be requested by written correspondence and any relevant infor-
mation obtained in this manner will be included in the review.
Disagreements will be resolved in consultation a third author.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (e.g. incidence of ESKD, mortality)
results will be expressed as risk ratio (RR) with 95% confidence
intervals (CI). Where continuous scales of measurement are used
to assess the effects of treatment (e.g. quality of life, body weight),
the mean difference (MD) will be used, or the standardised mean
difference (SMD) if different scales have been used.
Unit of analysis issues
Cluster RCTS will be analysed in one of two ways.
1. Using a statistical analysis that properly accounts for the
cluster design. Some examples of these are based on a ‘multi-level
model’, a ‘variance components analysis’ or may use ‘generalised
estimating equations’ (Higgins 2011).
2. Conduct the analysis treating the sample size as the number
of clusters and proceed as if the study was individually
randomised, treating the clusters as individuals.
When considering cross-over studies we will only use data from
the first period.
When considering studies with multiple treatment groups we will
try to combine all relevant experimental intervention groups of
the study into a single group and to combine all relevant control
intervention groups into a single group to enable single pair wise
comparison.
Dealing with missing data
Any further information required from the original author will be
requested by written correspondence (e.g. emailing corresponding
author) and any relevant information obtained in this manner
will be included in the review. Evaluation of important numerical
data such as screened, randomised patients as well as intention-
to-treat, as-treated and per-protocol population will be carefully
performed. Attrition rates, for example drop-outs, losses to follow-
up and withdrawals will be investigated. Issues of missing data
and imputation methods (for example, last-observation-carried-
forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
We will first assess the heterogeneity by visual inspection of the
forest plot.Heterogeneitywill thenbe analysed using aChi2 test on
N-1 degrees of freedom, with an alpha of 0.05 used for statistical
significance and with the I2 test (Higgins 2003). A guide to the
interpretation of I2 values will be as follows.
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity.
The importance of the observed value of I2 depends on the mag-
nitude and direction of treatment effects and the strength of evi-
dence for heterogeneity (e.g. P-value from the Chi2 test, or a con-
fidence interval for I2) (Higgins 2011).
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixed-
effect model will also be used to ensure robustness of the model
chosen and susceptibility to outliers.
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Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be used to explore possible sources of
heterogeneity (e.g. participants, interventions and study quality).
Heterogeneity among participants could be related to age, stage of
CKD or underlying concurrent disease states (e.g. diabetes). Het-
erogeneity in eHealth interventions could be related to the way
the intervention is delivered (e.g. one on one, internet-based, or
in groups), the content of the intervention (e.g. lifestyle interven-
tions or medication compliance interventions) or the duration of
the intervention.
If a meta-analysis is not possible, adverse effects will be tabulated
and assessed with descriptive techniques, as they are likely to be
different for the various interventions used. Where possible, the
risk difference with 95% CI will be calculated for each adverse
effect, either compared to no treatment or to another intervention.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008). The GRADE approach defines the quality of a
body of evidence as the extent to which one can be confident that
an estimate of effect or association is close to the true quantity of
specific interest. The quality of a body of evidence involves consid-
eration of within-trial risk of bias (methodological quality), direct-
ness of evidence, heterogeneity, precision of effect estimates and
risk of publication bias (Schünemann 2011b). We plan to present
the following outcomes in the ’Summary of findings’ tables.
The seven key outcomes to be included in the Summary of Find-
ings table are as follows.
• Change electrolyte management
• Change in fluid management
• Dietary intake and behaviours
• Physical activity behaviours
• Adherence to treatment
• Quality of life.
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Kidney Diseases] explode all trees
2. MeSH descriptor: [Renal Replacement Therapy] explode all trees
3. MeSH descriptor: [Renal Insufficiency] explode all trees
4. MeSH descriptor: [Renal Insufficiency, Chronic] explode all trees
5. dialysis:ti,ab,kw (Word variations have been searched)
6. hemodialysis or haemodialysis:ti,ab,kw (Word variations have been searched)
7. hemofiltration or haemofiltration:ti,ab,kw (Word variations have been searched)
8. hemodiafiltration or haemodiafiltration:ti,ab,kw (Word variations have been searched)
9. kidney disease* or renal disease* or kidney failure or renal failure:ti,ab,kw (Word variations have been searched)
10. ESRF or ESKF or ESRD or ESKD:ti,ab,kw (Word variations have been searched)
11. CKF or CKD or CRF or CRD:ti,ab,kw (Word variations have been searched)
12. CAPD or CCPD or APD:ti,ab,kw (Word variations have been searched)
13. predialysis or pre-dialysis:ti,ab,kw (Word variations have been searched)
14. {or #1-#13}
15. (sms or mms) and messag*:ti,ab,kw (Word variations have been searched)
16. apps:ti,ab,kw (Word variations have been searched)
17. text messag*:ti,ab,kw (Word variations have been searched)
18. multimedia messag*:ti,ab,kw (Word variations have been searched)
19. facebook*:ti,ab,kw (Word variations have been searched)
20. email*:ti,ab,kw (Word variations have been searched)
21. twitter* or tweet*:ti,ab,kw (Word variations have been searched)
22. social media*:ti,ab,kw (Word variations have been searched)
23. (mobile* or cell or smart*) and phone*:ti,ab,kw (Word variations have been searched)
24. ios or android:ti,ab,kw (Word variations have been searched)
25. ipad* or iphone* or ipod*:ti,ab,kw (Word variations have been searched)
26. tablet* and computer*:ti,ab,kw (Word variations have been searched)
27. (online or web*) and (education* or train*):ti,ab,kw (Word variations have been searched)
28. personal digital assistant*:ti,ab,kw (Word variations have been searched)
29. e-health or ehealth or mhealth or m-health or telehealth or telemedicine:ti,ab,kw (Word variations have been
searched)
30. {or #15-#29}
31. {and #14, #30}
MEDLINE 1. exp Telemedicine/
2. exp Internet/
3. exp communications media/
4. exp Programmed Instruction as Topic/
5. Computers, Handheld/
6. Mobile Applications/
7. exp Cell Phones/
8. ((sms or mms) and messag$).tw.
9. apps.tw.
10. “text messag$”.tw.
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(Continued)
11. multimedia messag$.tw.
12. facebook.tw.
13. email$.tw.
14. (twitter or tweet$).tw.
15. social media$.tw.
16. ((mobile$ or cell or smart$) and phone).tw.
17. (ios or android$).tw.
18. (ipad$ or iphone$ or ipod$).tw.
19. (tablet$ and computer$).tw.
20. ((online or web$) and (education$ or train$)).tw.
21. personal digital assistant$.tw.
22. (e-health or ehealth or mhealth or m-health or telehealth$ or telemedicine$).tw.
23. or/1-22
24. Kidney Diseases/
25. exp Renal Replacement Therapy/
26. Renal Insufficiency/
27. exp Renal Insufficiency, Chronic/
28. dialysis.tw.
29. (hemodialysis or haemodialysis).tw.
30. (hemofiltration or haemofiltration).tw.
31. (hemodiafiltration or haemodiafiltration).tw.
32. (kidney disease* or renal disease* or kidney failure or renal failure).tw.
33. (ESRF or ESKF or ESRD or ESKD).tw.
34. (CKF or CKD or CRF or CRD).tw.
35. (CAPD or CCPD or APD).tw.
36. (predialysis or pre-dialysis).tw.
37. or/24-36
38. and/23,37
EMBASE 1. exp telehealth/
2. exp mass communication/
3. exp mobile application/
4. ((sms or mms) and messag$).tw.
5. apps.tw.
6. “text messag$”.tw.
7. multimedia messag$.tw.
8. facebook.tw.
9. email$.tw.
10. (twitter or tweet$).tw.
11. social media$.tw.
12. ((mobile$ or cell or smart$) and phone).tw.
13. (ios or android$).tw.
14. (ipad$ or iphone$ or ipod$).tw.
15. (tablet$ and computer$).tw.
16. ((online or web$) and (education$ or train$)).tw.
17. personal digital assistant$.tw.
18. (e-health or ehealth or mhealth or m-health or telehealth$ or telemedicine$).tw.
19. or/1-18
20. exp renal replacement therapy/
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(Continued)
21. kidney disease/
22. chronic kidney disease/
23. kidney failure/
24. chronic kidney failure/
25. mild renal impairment/
26. stage 1 kidney disease/
27. moderate renal impairment/
28. severe renal impairment/
29. end stage renal disease/
30. renal replacement therapy-dependent renal disease/
31. kidney transplantation/
32. (hemodialysis or haemodialysis).tw.
33. (hemofiltration or haemofiltration).tw.
34. (hemodiafiltration or haemodiafiltration).tw.
35. dialysis.tw.
36. (CAPD or CCPD or APD).tw.
37. (kidney disease* or renal disease* or kidney failure or renal failure).tw.
38. (CKF or CKD or CRF or CRD).tw.
39. (ESRF or ESKF or ESRD or ESKD).tw.
40. (predialysis or pre-dialysis).tw.
41. ((kidney or renal) adj (transplant* or graft* or allograft*)).tw.
42. or/20-41
43. and/19,42
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimisation (minimisation may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
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(Continued)
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
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(Continued)
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardised difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. sub-scales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
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imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
C O N T R I B U T I O N S O F A U T H O R S
1. Draft the protocol: JS, JC, AW, KC, VL, CC
2. Study selection: JS, ZC
3. Extract data from studies: JS, ZC
4. Enter data into RevMan: JS, ZC
5. Carry out the analysis: JS, ZC
6. Interpret the analysis: JS, ZC
7. Draft the final review: JS, JC, AW, KC, VL, CC
8. Disagreement resolution: VL
9. Update the review: JS
D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• Centre for Kidney Research, The Children’s Hospital at Westmead, Australia.
External sources
• BEAT-CKD, Australia.
PhD Scholarship (through NHMRC project grant)
16eHealth interventions for people with chronic kidney disease (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
